Sep 2026· Journal of Visualized Experiments· Vol 235· 0 citations
Medicine
TL;DR
In silico findings provide new insights into the possible molecular mechanisms of plumbagin and offer a rationale for future experimental validation, however, further in vitro and in vivo studies are warranted to confirm its functional activity and therapeutic efficacy.
Abstract
Prostate cancer is a major contributor to cancer-related mortality among men. Because many patients are diagnosed only after the disease has progressed to a locally advanced or metastatic stage, curative treatment is often no longer possible. In the present study, we applied an integrated computational approach combining network pharmacology, molecular docking, and molecular dynamics simulations to explore the potential molecular mechanisms underlying the therapeutic effects of plumbagin in prostate cancer. Potential therapeutic targets were identified through integrated database analysis, followed by protein-protein interaction network construction, functional enrichment analysis, molecular docking, and molecular dynamics simulations to evaluate the stability of protein-ligand interactions. Our computational analyses identified that plumbagin may form stable interactions with multiple hub targets, including AKT serine/threonine kinase 1 (AKT1), estrogen receptor 1 (ESR1), BCL2 apoptosis regulator (BCL2), epidermal growth factor receptor (EGFR), tumor necrosis factor (TNF), mitogen-activated protein kinase 3 (MAPK3), heat shock protein 90 alpha family class A member 1 (HSP90AA1), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), and peroxisome proliferator activated receptor gamma (PPARG), suggesting its potential to modulate key pathways involved in prostate cancer progression. These in silico findings provide new insights into the possible molecular mechanisms of plumbagin and offer a rationale for future experimental validation. However, further in vitro and in vivo studies are warranted to confirm its functional activity and therapeutic efficacy.
CDK1 was identified as a promising therapeutic target, and Tucatinib emerged as the most promising repurposing candidate, warranting further clinical validation.
J. Rafiee, Seyedeh Tahereh Arabi Baygi, S. H. Aghaee-Bakhtiari· Computational biology and ch...· 0 citations
This study investigated Altissimacoumarin H (ATSC), a naturally occurring terpenylated coumarin, using an integrated in silico workflow combining target prediction, network pharmacology, transcriptomic assessment, molecular docking, molecular dynamics, ADME/toxicity prediction, and density functional theory (DFT).
S. Bufarwa, M. Belaidi· Journal of Computational Bio...· 0 citations
Breast cancer remains a leading cause of cancer-related mortality worldwide, with dysregulation of apoptosis contributing to tumour progression and therapeutic resistance. The anti-apoptotic protein Bcl-xL is a key regulator of apoptotic evasion and an attractive therapeutic target; however, currently available Bcl-x...
Gopika Gopakumar, T. Shenoy, A. A. Abdul Salam· Scientific Reports· 0 citations
Glioblastoma (GBM) is an aggressive primary brain tumor characterized by rapid progression, therapeutic resistance, and poor clinical outcomes. Curculigoside (CUR), a natural compound with anti-inflammatory and antitumor properties, has not been systematically investigated in GBM. This study aimed to investigate the an...
Jia-Wen Han, Zhan-Chuan Ma, Shan Lin et al.· Bioorganic chemistry (Print)· 0 citations
This computational approach successfully identified Bisphosphonate-8 as an inhibitor of the α-β tubulin dimer, with better binding affinity and stability than well-known compounds and desirable pharmacokinetic properties.